Skip to main content

Transcode Therapeutics Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

RNAZ$1.35-12.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page)

POWER OF ATTORNEY AND SIGNATURES

Each individual whose signature appears below hereby constitutes and appoints Thomas A. Fitzgerald, MBA as such person’s true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K and Power of Attorney has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

NAMETITLEDATE
​​​​​
/s/ Thomas A. Fitzgerald​Director, Interim Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)​April 1, 2024
Thomas A. Fitzgerald, MBA​​​​
​​​​​
/s/ Philippe P. Calais​Director, Executive Chairman​April 1, 2024
Philippe P. Calais, PhD​​​​
​​​​​
/s/ Erik Manting​Director​April 1, 2024
Erik Manting, PhD​​​​
​​​​​
/s/ Magda Marquet​​​​
Magda Marquet, PhD​Director​April 1, 2024

Table of Contents

​Page
Report of Independent Registered Public Accounting FirmF-2
Balance Sheets as of December 31, 2023 and 2022F-3
Statements of Operations for the Years Ended December 31, 2023 and 2022F-4
Statements of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022F-5
Statements of Cash Flows for the Years Ended December 31, 2023 and 2022F-6
Notes to Financial StatementsF-7
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.